Neuroprotective effect of cannabinoids nanoplatforms in neurodegenerative diseases

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Journal of Drug Delivery Science and Technology

• Publication date

  2017-12-01

• Fields of study

  Medicine, Materials Science

• Identifiers
  DOI 10.1016/J.JDDST.2017.04.023
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• The analgesic potential of cannabinoids.

  2018cited by this paper
• Cannabinoids prevent the amyloid β‐induced activation of astroglial hemichannels: A neuroprotective mechanism

  2017cited by this paper
• Carbon nanotube-anandamide complex exhibits sustained protective effects in an in vitro model of stroke

  2016cited by this paper
• Type-2 cannabinoid receptors in neurodegeneration.

  2016cited by this paper
• Antidepressant effects of curcumin and HU-211 coencapsulated solid lipid nanoparticles against corticosterone-induced cellular and animal models of major depression

  2016cited by this paper
• Encapsulation of cannabinoid drugs in nanostructured lipid carriers.

  2016cited by this paper
• Endocannabinoid System in Neurological Disorders.

  2016cited by this paper
• Biological characterization of PM226, a chromenoisoxazole, as a selective CB2 receptor agonist with neuroprotective profile.

  2016cited by this paper
• Lipid nanoparticles as an emerging platform for cannabinoid delivery: physicochemical optimization and biocompatibility

  2016cited by this paper
• In vitro and in vivo evaluation of Δ⁹-tetrahidrocannabinol/PLGA nanoparticles for cancer chemotherapy.

  2015cited by this paper
• Cannabinoid antagonist in nanostructured lipid carriers (NLCs): design, characterization and in vivo study.

  2015cited by this paper
• Promising cannabinoid-based therapies for Parkinson’s disease: motor symptoms to neuroprotection

  2015cited by this paper
• Efecto neuroprotector de los cannabinoides en las enfermedades neurodegenerativas

  2015cited by this paper
• Enhanced cellular uptake and biodistribution of a synthetic cannabinoid loaded in surface-modified poly(lactic-co-glycolic acid) nanoparticles.

  2014cited by this paper
• Engineering of Δ9-tetrahydrocannabinol delivery systems based on surface modified-PLGA nanoplatforms.

  2014cited by this paper
• Cannabinoids for treatment of Alzheimer’s disease: moving toward the clinic

  2014cited by this paper
• Cannabinoides: una prometedora herramienta para el desarrollo de nuevas terapias

  2014cited by this paper
• Delta-9-Tetrahydrocannabinol/Cannabidiol (Sativex®): A Review of Its Use in Patients with Moderate to Severe Spasticity Due to Multiple Sclerosis

  2014cited by this paper
• Apoptotic cell: linkage of inflammation and wound healing

  2014cited by this paper
• Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial

  2013cited by this paper
• Treatment of Huntington’s Disease

  2013cited by this paper
• Does Cannabidiol Protect Against Adverse Psychological Effects of THC?

  2013cited by this paper
• Chronic THC intake modifies fundamental cerebellar functions.

  2013cited by this paper
• Interés Terapéutico de Cannabinoides: Análisis Bibliométrico en PubMed, Scopus y Web of Science

  2013cited by this paper
• Local Delivery of Cannabinoid-Loaded Microparticles Inhibits Tumor Growth in a Murine Xenograft Model of Glioblastoma Multiforme

  2013cited by this paper
• Cannabinoid derivate-loaded PLGA nanocarriers for oral administration: formulation, characterization, and cytotoxicity studies

  2012cited by this paper
• Sativex-like combination of phytocannabinoids is neuroprotective in malonate-lesioned rats, an inflammatory model of Huntington's disease: role of CB1 and CB2 receptors.

  2012cited by this paper
• Innate Immunity in multiple sclerosis white matter lesions: expression of natural cytotoxicity triggering receptor 1 (NCR1)

  2012cited by this paper
• Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice

  2012cited by this paper
• The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis.

  2012cited by this paper
• Cannabinoid Modulation of Neuroinflammatory Disorders

  2012cited by this paper
• Involvement of hindbrain and peripheral prostanoids in gastric motor and cardiovascular responses to delta-9-tetrahydrocannabinol in the rat.

  2012cited by this paper
• [Treatment of spasticity in multiple sclerosis: new perspectives regarding the use of cannabinoids].

  2012cited by this paper
• Symptom‐relieving and neuroprotective effects of the phytocannabinoid Δ9‐THCV in animal models of Parkinson's disease

  2011cited by this paper
• Cannabinoid Neuroimmune Modulation of SIV Disease

  2011cited by this paper
• Nanostructures for drug delivery to the brain.

  2011cited by this paper
• Themed Issue: Cannabinoids in Biology and Medicine, Part I

  2011cited by this paper
• Cannabis and Amyotrophic Lateral Sclerosis: Hypothetical and Practical Applications, and a Call for Clinical Trials

  2010cited by this paper
• Lipid nanoparticles for parenteral delivery of actives.

  2009cited by this paper
• Potential applications of nanotechnologies to Parkinson's disease therapy.

  2008cited by this paper
• Cannabidiol: from an inactive cannabinoid to a drug with wide spectrum of action.

  2008cited by this paper
• Therapeutic potential of cannabis in pain medicine.

  2008cited by this paper
• Cannabinoids and the brain

  2008cited by this paper
• Cannabinoid receptors and their role in neuroprotection

  2007cited by this paper
• Cannabinoids in health and disease

  2007cited by this paper
• Alzheimer's disease; taking the edge off with cannabinoids?

  2007cited by this paper
• AM1241, a cannabinoid CB2 receptor selective compound, delays disease progression in a mouse model of amyotrophic lateral sclerosis.

  2006cited by this paper
• Astrocyte–endothelial interactions at the blood–brain barrier

  2006cited by this paper
• Spike timing of dendrite-targeting bistratified cells during hippocampal network oscillations in vivo

  2004cited by this paper
• Neuroprotective properties of cannabinoids against oxidative stress: role of the cannabinoid receptor CB1

  2002cited by this paper
• Pharmacology and potential therapeutic uses of cannabis.

  1998cited by this paper
• Increase in aqueous solubility, stability and in vitro corneal permeability of anandamide by hydroxypropyl-β-cyclodextrin

  1996cited by this paper

• "Exploring the Potential of Traditional Herbal Medicine in the Management of Central Nervous System Disorders"

  2025cites this paper
• Actividad antioxidante de variedades de cannabis del Norte del Cauca, Colombia

  2024cites this paper
• A rapid and accurate liquid chromatographic method for hemp compliance testing

  2024cites this paper
• Development of a liquid chromatographic method with a different selectivity for the quantification of eighteen phytocannabinoids in hemp

  2024cites this paper
• Exploring the Potential of Cannabinoid Nanodelivery Systems for CNS Disorders

  2023cites this paper
• Advances in nanotechnology versus stem cell therapy for the theranostics of Huntington's disease

  2023cites this paper
• Plants, phytochemicals, and natural practices in complementary and alternative system of medicine for treatment of central nervous system disorders

  2023cites this paper
• A Comprehensive Review on Cannabis sativa Ethnobotany, Phytochemistry, Molecular Docking and Biological Activities

  2023cites this paper
• Potency testing of up to sixteen cannabinoids in hemp-infused edibles using liquid chromatography diode array detector with optional confirmation of identity by electrospray ionization time-of-flight mass spectrometry.

  2023cites this paper
• The impact of phyto- and endo-cannabinoids on central nervous system diseases：A review

  2022cites this paper
• Development of a validated method for rapid quantification of up to sixteen cannabinoids using ultra-high-performance liquid chromatography diode-array detector with optional electrospray ionization time-of-flight mass spectrometry detection.

  2022cites this paper
• Cannabis for Medical Use: Versatile Plant Rather Than a Single Drug

  2022cites this paper
• Formulation of Nanomicelles Loaded with Cannabidiol as a Platform for Neuroprotective Therapy

  2022cites this paper
• Cognitive Deficiency in Cannabis Consumers

  2021cites this paper
• HPLC-DAD Analysis of Hemp Oil Supplements for Determination of Four Cannabinoids: Cannabidiol, Cannabidiolic Acid, Cannabinol and Delta 9-Tetrahydrocannabinol

  2021cites this paper
• Traditional Herbal Medicines Against CNS Disorders from Bangladesh

  2020cites this paper
• Recent Advances in Nanomedicines for Multiple Sclerosis Therapy.

  2020cites this paper
• Lipid nanocapsules decorated and loaded with cannabidiol as targeted prolonged release carriers for glioma therapy: In vitro screening of critical parameters

  2019cites this paper
• Cannabinoids for the Neuropsychiatric Symptoms of Dementia: A Systematic Review and Meta-Analysis

  2019cites this paper
• Nannocannabinoids for brain tumor drug delivery Title in Spanish : Nanocannabinoides como terapia frente a glioma

  2019cites this paper
• Implication des neurotransmetteurs

  2019cites this paper
• A new ESI-LC/MS approach for comprehensive metabolic profiling of phytocannabinoids in Cannabis

  2018cites this paper
• Antioxidant activity of non-psychoactive cannabis varieties from North Cauca, Colombia

  year unknowncites this paper